Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06772753 · ClinicalTrials.gov registry record · Phase 1
Investigation of Psychedelic Effects in Psychoactive Substances
A Phase 1 study of Psychedelic Effects in Healthy Volunteers, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06772753: Recruiting Phase 1 study of Psychedelic Effects in Healthy Volunteers, sponsored by Johns Hopkins University.
NCT06772753 is a Phase 1 study of Psychedelic Effects in Healthy Volunteers that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06772753, a Phase 1 study of Psychedelic Effects in Healthy Volunteers, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on the subjective effects of 6 different psychoactive substances or inactive placebo. Drug assignment for some sessions will be randomized (like flipping a count or rolling a pair of dice), and both participants and study staff will be blind to the drug condition on any given day. Participants will also complete 2 preparation sessions (4 hours total) before the first experimental session, and follow-up visits after each session to discuss and debrief on the participants subjective experience.
Primary Outcome
The MEQ is a 30-item self-report instrument intended to assess psychedelic-specific acute subjective effects of psychoactive drugs. At the end of each experimental session, participants will be instructed to rate each of the items of the MEQ relative to the experiences that the participant encountered during the course of the drug administration session. The total score on all items is then calculated as the primary outcome measure for each experimental session. Scores range from 0 to 150 on th
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ketamine
- DRUG Psilocybin
- DRUG Dextromethorphan (DXM)
- DRUG Dimethyltryptamine (DMT)
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-02-05 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT06772753 shows while recruiting
NCT06772753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Psychedelic Effects in Healthy Volunteers appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06772753 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06772753 about?
NCT06772753 is a clinical study titled "Investigation of Psychedelic Effects in Psychoactive Substances". The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, in...
What is the current status of trial NCT06772753?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-02-05. Estimated completion is 2027-12.
What conditions does trial NCT06772753 study?
This clinical trial studies the following conditions: Psychedelic Effects in Healthy Volunteers.
What interventions are being tested in trial NCT06772753?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Psilocybin (DRUG), Dextromethorphan (DXM) (DRUG), Dimethyltryptamine (DMT) (DRUG).
Who is sponsoring clinical trial NCT06772753?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06772753 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06772753's enrollment target sits among peer trials
50 974th of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI